Benin vs Sierra Leone: Average cost of multi drug-resistant tuberculosis treatment
Benin
426 constant 2022 US$
in 2024
Sierra Leone
369 constant 2022 US$
in 2024
Benin rank
86th
Sierra Leone rank
88th
Average cost of multi drug-resistant tuberculosis treatment over time
- Benin
- Sierra Leone
How they compare
Benin currently reports 426 constant 2022 US$ against 369 constant 2022 US$ in Sierra Leone, a difference of 57 constant 2022 US$.
That makes Benin's figure about 1.2 times Sierra Leone's.
The two have swapped places 1 time across 6 shared years of data; in 2017 it was Sierra Leone ahead.
Benin ranks 86th and Sierra Leone ranks 88th of 92 countries.
Sierra Leone has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Benin | Sierra Leone | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 1,013 constant 2022 US$ | 1,403 constant 2022 US$ | 390 constant 2022 US$ | Sierra Leone |
| 2020s | 770.33 constant 2022 US$ | 1,564 constant 2022 US$ | 793.33 constant 2022 US$ | Sierra Leone |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher average cost of multi drug-resistant tuberculosis treatment, Benin or Sierra Leone?
- Benin, at 426 constant 2022 US$ against 369 constant 2022 US$ in Sierra Leone as of 2024.
- What is the difference in average cost of multi drug-resistant tuberculosis treatment between Benin and Sierra Leone?
- 57 constant 2022 US$, with Benin ahead.
- How many years of comparable data are there for Benin and Sierra Leone?
- 6 years are reported by both, from 2017 to 2024.
- How do Benin and Sierra Leone rank globally for average cost of multi drug-resistant tuberculosis treatment?
- Benin ranks 86th and Sierra Leone ranks 88th of 92 countries.
- Where does this data come from?
- WHO (2025) – with minor processing by Our World in Data, published as Average cost of multi drug-resistant tuberculosis treatment. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Average cost of drugs spent per patient starting multidrug-resistant tuberculosis treatment, excluding buffer stock.